Reporting on pharma and biotech, @endpts. Baseball fan, Northwestern alum. Email: [email protected]
Joined May 2011
- Tweets12.3K
- Following482
- Followers2.1K
- Likes3.1K
Max Gelman retweeted
BREAKING: Novo Nordisk's CagriSema fails to hit 25% weightloss benchmark in Phase 3 readout. Novo’s stock $NVO crashed by as much as 26% pre-market Friday.
endpts.com/novo-reveals-23-w…
Max Gelman retweeted
This will be one to watch. Sorriso says it has figured out how to make an orally-administered antibody, and is claiming success in Phase 1b study in ulcerative colitis. @MaxGelman has the details for @endpts - endpts.com/sorriso-claims-a-…
Max Gelman retweeted
Two outstanding pieces by @kakape on misinformation, open-access, @ScienceMagazine
science.org/content/article/…
science.org/content/article/…
Max Gelman retweeted
What would RFK Jr. do on healthcare? Trump ally's FDA plans raise alarm - endpts.com/what-would-rfk-jr…
Max Gelman retweeted
Evergreen reminder to always double check who you’re emailing before hitting send
Ex-Pfizer CFO emailed CEO Albert Bourla over the weekend. The message was blank. But the “to” field included a rep for activist Starboard
From @ArmstrongDrew @maxonwifi
endpts.com/behind-the-scenes…
Max Gelman retweeted
This year’s Women in Biopharma R&D report is dedicated to Natalie Grover, who launched the project with @AmberTongPW in 2019 while they were working at Endpoints. We’re proud to continue their tradition of honoring 20 exceptional women leaders.
endpts.com/special-report-20…
Max Gelman retweeted
Lykos Therapeutics was on the precipice of bringing the first genuine psychedelic medicine to market. It was the culmination of almost 40 years of work. And then in a matter of months, the company nearly crumbled. Our @endpts story on how that happened. endpts.com/bad-trip-how-cult…
Max Gelman retweeted
That’s a wrap! Today I sent my last Early Edition for @endpts — my first job out of college, my mini medical / biopharma degree, the place that will always have a special place in my heart.
Max Gelman retweeted
NEW: A moment of truth is coming for Recursion
@MaxGelman & I dove into what imminent clinical data could mean for $RXRX and for the broader AI bio field:
endpts.com/recursion-nears-m…
Max Gelman retweeted
1st round of CMS negotiated drug prices under the IRA are LIVE: endpts.com/federal-governmen…
Max Gelman retweeted
Very humbled by this award, which has gone to some of my favorite science writers over the years.
And thankful to all the sources — parents, advocates, scientists — who gave parts of their very scarce time for these pieces
Congratulations to @Jasonmmast of @statnews for winning the 2024 Evert Clark/Seth Payne Award! The judges called his work on the genetics of disease moving, thought-provoking, and creative.
Jason will be honored at #SciWri24 in November.
More: casw.org/news/jason-mast-win…
Max Gelman retweeted
I met with @PhRMA's Stephen Ubl this week for a wide-ranging conversation on Medicare negotiations, the legal fight against the IRA, US tensions with China, the FDA's decision-making authority, and more. Read more here:
endpts.com/qa-phrma-ceo-step…
Max Gelman retweeted
Leqembi-treated patients progressed about 1.2 points on a scale of cognitive decline in the first 18 months and 3.09 points by 36 months. Eisai estimated that without the drug, patients would have progressed 4.04 points.
More in my story for @endpts: endpts.com/eisai-says-alzhei…
Max Gelman retweeted
For 3.5 years, I followed teenager Connor Dalby and family while a custom treatment was developed for his seizures.
The journey revealed a lot about personalized medicine's failures, and promise.
endpts.com/a-teenager-faced-…
Max Gelman retweeted
The next chunk in @endpts' pay analysis series:
Median employee pay data on 177 biopharmas
Check out *all* the data here, ranging from median workers getting paid <$500k to $11k:
endpts.com/biotech-salary-an…
Max Gelman retweeted
Arc Institute scientist @pdhsu has unveiled new way to make large changes to genes. No CRISPR necessary.
A newly discovered "bridge RNA" connects a bacterial recombinase to a target and donor DNA to make insertions, deletions, and inversions.
@endpts: endpts.com/scientists-unveil…
Max Gelman retweeted
Lykos' knockdown at the hands of FDA advisors cast an immediate cloud over the psychedelic industry. But with the dust settled, competitors chasing the MDMA developer are confident, if not emboldened. A look at the race with the great @Ayisha_Sharma97: endpts.com/lykos-pain-is-oth…
Max Gelman retweeted
spoke to lots of people today + they feel many different ways about the top FDA official Peter Marks' decision to approve Sarepta's DMD gene therapy
my story in @endpts:
endpts.com/fdas-peter-marks-…
Max Gelman retweeted
NEW: I went in the lab of Iambic Therapeutics to see how the San Diego startup actually uses AI to develop drugs
It's not just an idea — Iambic's first AI-designed drug is in the clinic, and a 2nd program is close behind
A name to know in the AI space:
endpts.com/how-two-academic-…
Max Gelman retweeted
Reminder that the mifepristone decision for pharma and FDA was about much more than abortion politics. Decision had potential to completely alter US drug approval process. Oral arguments hinted though that, that was unlikely.
pink.citeline.com/PS150021/F…